Brought to you by 
Capstone Therapeutics, LipimetiX form JV
30 Jan 2023
Executive Summary
Cardiovascular/metabolic drug developer Capstone Therapeutics Corp. has formed a joint venture, LipimetiX Development LLC (LD), with LipimetiX LLC (commercializes IP discovered at the University of Alabama, Birmingham) to work on medications that lower blood cholesterol levels.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Capstone Therapeutics, LipimetiX form JV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice